

C-Path Appoints Biotech Executive and Investor Dr. Milad Alucozai to Board of Directors

TUCSON, Ariz., June 11, 2026 — Critical Path Institute® (C-Path) today announced the appointment of Milad Alucozai, DrPH, MPH, M.Sc., to its Board of Directors. Dr. Alucozai is a longtime leader in the U.S. biotechnology and startup community who has worked as a founder, investor, operator, and community builder, and is the creator of the Bio-Industrial Technology Stack (BITS) framework, which reframes biology as a geopolitical and industrial asset. A neuroscientist and startup investor, he bridges computational biology, machine learning, and AI-driven drug development. His appointment reflects the organization’s commitment to integrating emerging biotechnology and human-relevant research models into its global mission of accelerating safer, more effective treatments.



Milad Alucozai, DrPH

Alucozai is co-founder and general partner of Pamir Ventures, which he launched with Roger Ferguson, former vice chairman of the U.S. Federal Reserve. The firm serves as the first check for technical pioneers building breakthrough companies that redefine markets. He is also co-founder and board member of Revalia Bio, a human-biology data infrastructure company. Through its Human Data Stack, Revalia transforms non-transplantable donated human organs and tissues into high-fidelity biological data for drug development, generating an entirely new source of clinically relevant human insight.

Recognized by Business Insider in 2025 as one of the top 100 early-stage investors, he currently serves as an external advisor to Amgen and as a member of the Advisory Committee at the Wyss Institute for Biologically Inspired Engineering at Harvard University.

Over the course of his career, Alucozai has helped companies raise hundreds of millions of dollars in venture capital and supported billions of dollars in startup-pharma partnerships and co-development deals. He previously served as an external advisor to AstraZeneca and supported \$1.5 billion in non-dilutive Advanced Research Projects Agency for Health (ARPA-H) funding as an Expert in Residence through Digitalis Commons.

“Milad’s scientific training, his years of founding and funding companies at the frontier of biology and computation, his work advising ARPA-H and his deep and unwavering belief that drug development must be built on human data rather than approximations make him an extraordinary addition to this board,” said M. Wainwright Fishburn, J.D., chairman of the board at C-Path. “On behalf of the entire board, we are so grateful he is joining us, and we look forward to working alongside him.”

“Milad is a scientist, a founder, a strategist, and an investor whose entire career has been devoted to some of the hardest and most important problems in medicine,” said C-Path CEO Klaus Romero, M.D., M.S., FCP. “His rigor, his creativity, and his genuine commitment to the people waiting for innovative treatments are exactly what this organization stands for. I look forward to everything we will accomplish together.”

“I’m a builder at heart, and I’m joining C-Path because I believe it’s one of the most important organizations in medicine — and one of the most exciting,” said Alucozai. “For more than 20 years, C-Path has done the hard, patient work of earning trust across competitors, regulators and patient advocates. That foundation is exactly what makes the road ahead so promising. I can’t wait to help write the next chapter, and to do it for the patients depending on all of us.”

Dr. Alucozai graduated Phi Beta Kappa in neuroscience from Purdue University’s Honors Program, earned a master’s degree in immunology and public health from Maynooth University, and holds a doctorate from the Indiana University Richard M. Fairbanks School of Public Health. He also completed a Visiting Scholar appointment at the Wyss Institute for Biologically Inspired Engineering at Harvard University.

The appointment is effective immediately.

About Critical Path Institute

Critical Path Institute® (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 56% funded by the FDA/HHS, totaling \$23,740,424, and 44% funded by non-government source(s), totaling \$18,881,611. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.

Media Contacts:

Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org

Kissy Black
C-Path
615.310.1894
kblack@c-path.org